The Lancet Respiratory Medicine

, volume 12 , issue 10 , pages 787-798

Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

Charles S. Haworth ¹

Michal Shteinberg ²

Kevin Winthrop ³

ALAN R. BARKER ⁴

Francesco Blasi ⁵

Katerina Dimakou ⁶

Lucy S. Morgan ⁷

Anne E. O'Donnell ⁸

Felix C. Ringshausen ⁹

Oriol Sibila ¹⁰

Rachel Thomson ¹¹

Kevin J. Carroll ¹²

Federica Pontenani ¹³

Paola Castellani ¹³

James Chalmers ¹⁴

Hide authors affiliations Show authors affiliations: 14 affiliations

Cambridge Centre for Lung Infection, Royal Papworth Hospital and University of Cambridge, Cambridge, UK. |

Pulmonology Institute and CF Center, Carmel Medical Center, Haifa, Israel; Technion Israel Institute of Technology, the B Rappaport Faculty of Medicine, Haifa, Israel.

Technion – Israel Institute of Technology

Carmel Medical Center

Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA. |

⁴

Department of Pulmonary and Critical Care Medicine, Oregon Health and Science University, Portland, OR, USA. |

⁵

Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy; Respiratory Unit and Cystic Fibrosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy. |

⁶

5th Respiratory Medicine Department, General Hospital for Chest Diseases of Athens Sotiria, Athens, Greece. |

⁷

Department of Respiratory Medicine, Concord Repatriation General Hospital, Concord, NSW, Australia; University of Sydney, Sydney, NSW, Australia.

University of Sydney

Concord Repatriation General Hospital

⁸

Division of Pulmonary, Critical Care and Sleep Medicine, Georgetown University Medical Center, Washington, DC, USA. |

⁹

Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover, German Center of Lung Research, Hannover, Germany; European Reference Network on Rare and Complex Respiratory Diseases, Frankfurt, Germany.

Hannover Medical School

German Center for Lung Research

¹⁰

Department of Respiratory Medicine, Hospital Clinic of Barcelona, University of Barcelona, Centro de Investigacion Biomedica En Red Enfermedades Respiratorias, Institut d Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.

Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer

Hospital Clínic de Barcelona

Centro de Investigación Biomédica en Red de Enfermedades Respiratorias

¹¹

Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Brisbane, QLD, Australia; University of Queensland, Brisbane, QLD, Australia. |

¹²

KJC Statistics Ireland, Dublin, Ireland. |

¹³

Research and Development Department. Zambon SpA, Bresso, Milan, Italy. |

¹⁴

Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, UK. Electronic address: j.chalmers@dundee.ac.uk. |

Publication type: Journal Article

Publication date: 2024-10-01

Elsevier

The Lancet Respiratory Medicine

scimago Q1

wos Q1

SJR: 6.788

CiteScore: 53.2

Impact factor: 32.8

ISSN: 22132600, 22132619

DOI: 10.1016/s2213-2600(24)00225-x

Copy DOI

PubMed ID: 39270696

Abstract

Chronic lung infection with Pseudomonas aeruginosa is associated with increased exacerbations and mortality in people with bronchiectasis. The PROMIS-I and PROMIS-II trials investigated the efficacy and safety of 12-months of inhaled colistimethate sodium delivered via the I-neb.

Found

Top-30

Journals

	1 2 3
European Respiratory Journal	European Respiratory Journal, 3, 18.75% European Respiratory Journal 3 publications, 18.75%
The Lancet Respiratory Medicine	The Lancet Respiratory Medicine, 1, 6.25% The Lancet Respiratory Medicine 1 publication, 6.25%
Pneumologie	Pneumologie, 1, 6.25% Pneumologie 1 publication, 6.25%
Expert Review of Respiratory Medicine	Expert Review of Respiratory Medicine, 1, 6.25% Expert Review of Respiratory Medicine 1 publication, 6.25%
Antibiotics	Antibiotics, 1, 6.25% Antibiotics 1 publication, 6.25%
JAMA - Journal of the American Medical Association	JAMA - Journal of the American Medical Association, 1, 6.25% JAMA - Journal of the American Medical Association 1 publication, 6.25%
Journal of Drug Targeting	Journal of Drug Targeting, 1, 6.25% Journal of Drug Targeting 1 publication, 6.25%
Thorax	Thorax, 1, 6.25% Thorax 1 publication, 6.25%
American Journal of Respiratory and Critical Care Medicine	American Journal of Respiratory and Critical Care Medicine, 1, 6.25% American Journal of Respiratory and Critical Care Medicine 1 publication, 6.25%
International Journal of COPD	International Journal of COPD, 1, 6.25% International Journal of COPD 1 publication, 6.25%
Respiratory Medicine and Research	Respiratory Medicine and Research, 1, 6.25% Respiratory Medicine and Research 1 publication, 6.25%
Lung India	Lung India, 1, 6.25% Lung India 1 publication, 6.25%
Respiratory Investigation	Respiratory Investigation, 1, 6.25% Respiratory Investigation 1 publication, 6.25%
Journal of Thoracic Disease	Journal of Thoracic Disease, 1, 6.25% Journal of Thoracic Disease 1 publication, 6.25%
	1 2 3

Publishers

	1 2 3
Elsevier	Elsevier, 3, 18.75% Elsevier 3 publications, 18.75%
Taylor & Francis	Taylor & Francis, 3, 18.75% Taylor & Francis 3 publications, 18.75%
European Respiratory Society (ERS)	European Respiratory Society (ERS), 3, 18.75% European Respiratory Society (ERS) 3 publications, 18.75%
Georg Thieme Verlag KG	Georg Thieme Verlag KG, 1, 6.25% Georg Thieme Verlag KG 1 publication, 6.25%
MDPI	MDPI, 1, 6.25% MDPI 1 publication, 6.25%
American Medical Association (AMA)	American Medical Association (AMA), 1, 6.25% American Medical Association (AMA) 1 publication, 6.25%
BMJ	BMJ, 1, 6.25% BMJ 1 publication, 6.25%
American Thoracic Society	American Thoracic Society, 1, 6.25% American Thoracic Society 1 publication, 6.25%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 6.25% Ovid Technologies (Wolters Kluwer Health) 1 publication, 6.25%
AME Publishing Company	AME Publishing Company, 1, 6.25% AME Publishing Company 1 publication, 6.25%
	1 2 3

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Haworth C. S. et al. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months // The Lancet Respiratory Medicine. 2024. Vol. 12. No. 10. pp. 787-798.

GOST all authors (up to 50) Copy

Haworth C. S., Shteinberg M., Winthrop K., BARKER A. R., Blasi F., Dimakou K., Morgan L. S., O'Donnell A. E., Ringshausen F. C., Sibila O., Thomson R., Carroll K. J., Pontenani F., Castellani P., Chalmers J. Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months // The Lancet Respiratory Medicine. 2024. Vol. 12. No. 10. pp. 787-798.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1016/s2213-2600(24)00225-x

UR - https://linkinghub.elsevier.com/retrieve/pii/S221326002400225X

TI - Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months

T2 - The Lancet Respiratory Medicine

AU - Haworth, Charles S.

AU - Shteinberg, Michal

AU - Winthrop, Kevin

AU - BARKER, ALAN R.

AU - Blasi, Francesco

AU - Dimakou, Katerina

AU - Morgan, Lucy S.

AU - O'Donnell, Anne E.

AU - Ringshausen, Felix C.

AU - Sibila, Oriol

AU - Thomson, Rachel

AU - Carroll, Kevin J.

AU - Pontenani, Federica

AU - Castellani, Paola

AU - Chalmers, James

PY - 2024

DA - 2024/10/01

PB - Elsevier

SP - 787-798

IS - 10

VL - 12

PMID - 39270696

SN - 2213-2600

SN - 2213-2619

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2024_Haworth,

author = {Charles S. Haworth and Michal Shteinberg and Kevin Winthrop and ALAN R. BARKER and Francesco Blasi and Katerina Dimakou and Lucy S. Morgan and Anne E. O'Donnell and Felix C. Ringshausen and Oriol Sibila and Rachel Thomson and Kevin J. Carroll and Federica Pontenani and Paola Castellani and James Chalmers},

title = {Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months},

journal = {The Lancet Respiratory Medicine},

year = {2024},

volume = {12},

publisher = {Elsevier},

month = {oct},

url = {https://linkinghub.elsevier.com/retrieve/pii/S221326002400225X},

number = {10},

pages = {787--798},

doi = {10.1016/s2213-2600(24)00225-x}

}

MLA

Cite this

MLA Copy

Haworth, Charles S., et al. “Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months.” The Lancet Respiratory Medicine, vol. 12, no. 10, Oct. 2024, pp. 787-798. https://linkinghub.elsevier.com/retrieve/pii/S221326002400225X.

Publisher

Elsevier

Journal

The Lancet Respiratory Medicine

scimago Q1

wos Q1

SJR

6.788

CiteScore

53.2

Impact factor

32.8

ISSN

22132600 (Print)

22132619 (Electronic)

Profiles

Kevin L Winthrop